{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:07:32Z","timestamp":1762542452823},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.coviro.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,8,15]],"date-time":"2015-08-15T15:15:56Z","timestamp":1439651756000},"page":"50-55","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Effect of IL28B genotype on hepatitis B and C virus infection"],"prefix":"10.1016","volume":"14","author":[{"given":"Albert Friedrich","family":"St\u00e4ttermayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2015.07.011_bib0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.coviro.2015.07.011_bib0300","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0305","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1172\/JCI34772","article-title":"HapMap harvest of insights into the genetics of common disease","volume":"118","author":"Manolio","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2015.07.011_bib0310","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/apt.12717","article-title":"Review article: genetic factors that modify the outcome of viral hepatitis","volume":"39","author":"St\u00e4ttermayer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2015.07.011_sbref0315","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.07.011_bib0320","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","article-title":"Impact of IL28B genotype on the early and sustained virologic response in treatment-na\u00efve patients with chronic hepatitis C","volume":"4","author":"St\u00e4ttermayer","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0325","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0330","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep.23624","article-title":"Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes","volume":"52","author":"Montes-Cano","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0335","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.coviro.2015.07.011_bib0340","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0345","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.coviro.2015.07.011_bib0350","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.23976","article-title":"Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients","volume":"53","author":"Yu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0355","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.24154","article-title":"IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection","volume":"53","author":"Moghaddam","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0360","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/gutjnl-2012-302019","article-title":"IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5","volume":"61","author":"Antaki","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2015.07.011_bib0365","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/jvh.12047","article-title":"Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection","volume":"20","author":"Seto","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.coviro.2015.07.011_sbref0370","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with different expression of intrahepatic interferon stimulated genes in patients with chronic hepatitis C","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0375","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0380","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jhep.2010.09.019","article-title":"IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy","volume":"54","author":"Abe","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_sbref0385","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Gen"},{"key":"10.1016\/j.coviro.2015.07.011_bib0390","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/emboj.2013.232","article-title":"Interferon lambda 4 signals via the IFNk receptor to regulate antiviral activity against HCV and coronaviruses","volume":"32","author":"Hamming","year":"2013","journal-title":"EMBO"},{"key":"10.1016\/j.coviro.2015.07.011_bib0395","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/apt.12547","article-title":"Polymorphisms of interferon-\u03bb4 and IL28B\u2014effect on treatment response to interferon\/ribavirin in patients with chronic hepatitis C","volume":"39","author":"St\u00e4ttermayer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2015.07.011_bib0400","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.20130012","article-title":"IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction","volume":"210","author":"Bibert","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0405","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0410","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0415","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2015.07.011_bib0420","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1016\/S0168-8278(11)61371-8","article-title":"Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial","volume":"54","author":"Jacobson","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2015.07.011_bib0425","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT or TT in prior relapser, partial or null-responder patients treated with telaprevir\/peginterferon\/ribavirin: retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0430","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0435","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.07.011_bib0440","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0445","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0450","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2015.07.011_bib0455","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0460","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0465","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0470","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0475","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2015.07.011_bib0480","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0485","doi-asserted-by":"crossref","first-page":"ofu110","DOI":"10.1093\/ofid\/ofu110","article-title":"Subgroup differences in response to 8 weeks of ledipasvir\/sofosbuvir for chronic hepatitis C","volume":"1","author":"O\u2019Brien","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coviro.2015.07.011_sbref0490","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/infdis\/jit827","article-title":"IFNL4-\u0394G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin","volume":"209","author":"Meissner","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2015.07.011_bib0495","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0500","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_sbref0505","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.07.011_bib0510","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.gastro.2011.09.039","article-title":"Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection","volume":"142","author":"Beinhardt","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0515","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0520","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology."},{"key":"10.1016\/j.coviro.2015.07.011_bib0525","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2013.06.028","article-title":"A prognostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection","volume":"59","author":"Beinhardt","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0530","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/hep.27344","article-title":"Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus","volume":"61","author":"Hoffmann","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.coviro.2015.07.011_bib0535","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.12631","article-title":"Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?","volume":"39","author":"Galmozzi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2015.07.011_bib0540","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2011.11.025","article-title":"Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B","volume":"142","author":"Sonnenveld","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0545","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.25749","article-title":"IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAgnegative patients with chronic hepatitis B","volume":"57","author":"Lampertico","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2015.07.011_bib0550","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2011.12.009","article-title":"Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese","volume":"93","author":"Wu","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2015.07.011_bib0555","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/cid\/cit121","article-title":"HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B","volume":"56","author":"Seto","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2015.07.011_bib0560","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/liv.12491","article-title":"Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B","volume":"35","author":"Wu","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.coviro.2015.07.011_bib0565","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jgh.12110","article-title":"IL28B genotype is not useful for predicting treatment outcomes in Asian chronic hepatitis B patients treated with pegylated-interferon-a","volume":"28","author":"Holmes","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0570","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/00365521.2011.648952","article-title":"Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peginterferon alfa-2a and adefovir","volume":"47","author":"de Niet","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coviro.2015.07.011_bib0575","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jvh.12177","article-title":"IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients","volume":"21","author":"Zhang","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2015.07.011_bib0580","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3851\/IMP1841","article-title":"Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy","volume":"16","author":"Tseng TC1","year":"2011","journal-title":"Antivir Ther"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715001091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715001091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T08:35:00Z","timestamp":1572770100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625715001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":58,"alternative-id":["S1879625715001091"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2015.07.011","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of IL28B genotype on hepatitis B and C virus infection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}